Rivastigmine as a treatment in delirium; a pilot study

Delirium after stroke and treatment with rivastigmine; a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28018

Enrollment

Registered

2008-08-05

Start date

2004-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium stroke (dutch

Interventions

Rivastigmine 1.5 b.i.d, with an increase every other day with 3 mg to a maximum of 6 mg b.i.d

Eligibility

Inclusion criteria

Inclusion criteria: 1. Recent stroke 2. Persistent delirium 3. Severe delirium

Exclusion criteria

Exclusion criteria: 1. Prior adverse effects of rivastigmine 2. Severe renal failure 3. Age < 18 years 4. Women of child bearing potential 5. Use of any other investigational agent in the last 30 days

Design outcomes

Primary

Measure	Time frame
Presence of delirium measured with confusion assessment method and delirium rating scal	—

Secondary

Measure	Time frame
- Duration of delirium - Other medication needed	—

Contacts

Public ContactG. Roks

St Elisabeth Hospital Department of Neurology PO box 90151

g.roks@elisabeth.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)